tiprankstipranks
Analyst Profile
Followed by 200 other investors
.
Jonathan Wolleben

Jonathan Wolleben

JMP Securities
Wall Street Analyst
Ranked #6,063 out of 8,014 Analysts on TipRanks (#16,287 out of 21,455 overall experts)

Success Rate

45%
54 out of 121 Profitable Transactions

Average Return

-1.30%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Jonathan Wolleben's ratings since 2021 and opened each position for the duration of 1 Year:
44.63% of your transactions would have been profitable with an average return of -1.3%

Stock Rating Distribution

186Ratings
90.86% Buy
9.14% Hold
0.00% Sell
Distribution of Jonathan Wolleben's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
BioCryst Pharmaceuticals
(BCRX)
Rating Type:Buy
Dates:Jun 26, 2020 - Jun 26, 2021
Gain:254.60%
The most profitable rating made by Jonathan Wolleben

Jonathan Wolleben's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Strongbridge Biopharma
Hold
Assigned
50%
+19.30%
3
Larimar Therapeutics
Buy
Reiterated
$8.00
(325.51% Upside)
0%
-55.13%
8
Pharvaris
Buy
Initiated
$34.00
(100.00% Upside)
0%
-0.10%
1
Crinetics Pharmaceuticals
Buy
Reiterated
$42.00
(93.01% Upside)
57%
+2.57%
9
Aura Biosciences Inc
Buy
Initiated
$26.00
(36.38% Upside)
100%
+29.40%
1
Altimmune
Buy
Reiterated
$22.00
(69.49% Upside)
53%
+19.39%
26
DBV Technologies SA - American
Buy
Reiterated
$5.00
(86.57% Upside)
78%
+41.09%
10
Madrigal Pharmaceuticals
Buy
Reiterated
$180.00
(140.83% Upside)
20%
-10.27%
15
BioCryst
Buy
Reiterated
$24.00
(61.73% Upside)
71%
+37.85%
22
Intercept Pharma
Hold
Reiterated
0.00%
15
List of latest recommendations made by Jonathan Wolleben. Click to expand and see Jonathan Wolleben's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More